Tekon to provide CROs with technology from Labcyte for compound management, high-throughput, and secondary screening
Subscribe to our email newsletter
Labcyte has selected Tekon Biotech as its distributor in China, including Hong Kong and Taiwan.
Stephen Bates, SVP of sales, marketing and service of Labcyte, said: “As we expand in Asia, Tekon will help us broaden our existing user base in the pharmaceutical industry and the contract research organizations (CROs) that service them. Tekon will provide them with technology from Labcyte for compound management, high-throughput and secondary screening.
Our established customers in China will find that Tekon will give them an opportunity for more immediate support and interaction. Tekon will also introduce us to new users in the growing genomics market. We feel that with the Labcyte platforms, Tekon can meet the genomics customers’ needs for miniaturization, precision and accuracy while remaining contamination-free,” he added.
David Hadfield, CEO of Tekon Biotech, said: “We are very excited to be chosen by Labcyte as their partner in China, it is a tremendous validation of our efforts to provide the best possible support to our customers. We see a great potential market for low-volume transfer devices in China. We believe that the growing genomics markets, especially for gene expression, SNP analysis and RNAi, will find that the need for miniaturization is met particularly well by the Labcyte technologies. It is our goal to represent only the industry leading products in every category. Labcyte offers unique, touchless liquid handling systems. Our customers will have optimal interactions with a local group while reaping the benefits of the best available technology.”
Nick Samaras, managing director of Labcyte, said: “As the market moves to higher-density assays, the touchless liquid handling capabilities offered by the Labcyte acoustic products becomes essential. In particular, our Echo liquid handler provides superior results, reduces costs by eliminating consumables and reduces toxic wastes. Our platform technology is also being applied in other fields such as array formation, the microencapsulation of compounds, particle production, proteomics research, the transfer of ultra-viscous materials, cell-based biology and imaging mass spectrometry.”